# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Henry Holliday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI007-SYN-TD
- Date: 1873-02-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Martin Beaumont, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week follow-up on tuberculosis treatment, seen the same day by infectious diseases. **S**

## History of present illness

Mr. Holliday is a 21-year-old dentist with cavitary pulmonary tuberculosis who returns two weeks after diagnosis and is seen by infectious diseases today. He started isoniazid, rifampin, pyrazinamide, ethambutol, and pyridoxine two days after the first visit, once the nucleic acid amplification test confirmed tuberculosis, and has taken all thirteen doses on daily video calls with the health department nurse. His cough is less frequent, the blood streaks in his sputum have stopped, and the night sweats are lighter. He has mild nausea in the hour after the morning doses, eased by taking them at bedtime with a small snack. His urine and tears are orange, as he was warned. He has no yellowing, dark urine, abdominal pain, rash, numbness, or change in vision or color. He is isolating at home and not working; his roommate is being tested by the health department. He has cut down to a drink or two on three evenings in the two weeks and has not played cards. He feels low about being away from his practice but has no thoughts of suicide. **S**

| Element | Detail |
|---|---|
| Treatment | Thirteen of thirteen doses observed by video |
| Symptoms | Less cough, no further blood in the sputum, lighter night sweats |
| Side effects | Mild nausea after morning doses; orange urine and tears |
| Alcohol | Cut down; AUDIT-C 4 for the past two weeks |
| Isolation | At home; off work |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Cough less frequent; no blood in the sputum for a week; no breathlessness |
| Constitutional | Positive | Lighter night sweats; no fever for five days; appetite returning |
| Gastrointestinal | Positive | Mild nausea after doses; no vomiting, abdominal pain, or jaundice |
| Eyes | Negative | No blurred vision or change in color vision |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Positive | Low about isolation and time off work; no thoughts of suicide or self-harm |

6 systems reviewed. **S**

## Current medications

- Isoniazid 300 mg tablet, one tablet daily **S**
- Rifampin 300 mg capsules, two capsules (600 mg) daily **S**
- Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily **S**
- Ethambutol 400 mg tablets, three tablets (1200 mg) daily **S**
- Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 114/72 mmHg; pulse 92 bpm; respirations 18/min; temperature 37.3 °C; oxygen saturation 96% on room air; weight 59 kg; BMI 18.6 kg/m². All vital signs are synthetic.

ALT: 41 U/L; AST: 39 U/L; Total bilirubin: 0.7 mg/dL; Visual acuity, right eye (ETDRS letters): 85; Visual acuity, left eye (ETDRS letters): 84; AUDIT-C: 4. All results are synthetic.

## Change since baseline

- ALT: 34 U/L at baseline, 41 U/L at this visit **S**
- AST: 38 U/L at baseline, 39 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.7 mg/dL at this visit **S**
- Visual acuity, right eye (ETDRS letters): 85 at baseline, 85 at this visit **S**
- Visual acuity, left eye (ETDRS letters): 85 at baseline, 84 at this visit **S**
- AUDIT-C: 9 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, less tired; weight 59.0 kg, up 1.0 kg; temperature 37.3 °C, heart rate 92; seen in a negative-pressure room with a respirator |
| Eyes | No icterus. Visual acuity 85 letters on the right and 84 on the left; Ishihara plates read correctly with each eye |
| Respiratory | Coarse crackles and bronchial breathing over the right upper zone, less than two weeks ago |
| Abdomen | Soft and non-tender; liver not enlarged |
| Neurological | Normal sensation and reflexes in the feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Cavitary pulmonary tuberculosis, intensive phase** (A15.0). Early clinical response and full adherence. Baseline sputum cultures are growing Mycobacterium tuberculosis complex; susceptibility results are pending. ALT 41, AST 39, and bilirubin 0.7 at two weeks, all normal. Vision normal on ethambutol. HIV negative; hepatitis B and C serology negative, with no hepatitis B immunity. Infectious diseases agrees with the standard regimen and plan. **S**
   - Continue the four drugs and pyridoxine daily by video-observed therapy, taken at bedtime with a snack.
   - Three sputum samples on consecutive mornings in one week for the release decision.
   - Stop ethambutol once the isolate is shown to be susceptible to isoniazid and rifampin.
   - Liver tests monthly throughout treatment; stop the doses and call the same day for hepatitis symptoms.
2. **Alcohol use disorder, mild** (F10.10). Drinking already cut down. Safety reviewed: no thoughts of suicide. **S**
   - Goal agreed: no alcohol until treatment ends.
   - First session with a substance-use counselor by video next week.
   - Medication offered (acamprosate, which does not affect the liver); he prefers counseling first.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | At least monthly during treatment | Completed today | Cough and night sweats improving; no hemoptysis for a week |
| Examination | Weight | At least monthly during treatment | Completed today | 59.0 kg, up 1.0 kg |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | Mild nausea only, eased by bedtime dosing; no jaundice, dark urine, or pain |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline, at two weeks, then monthly because of alcohol use | Completed today | ALT 41, AST 39 U/L, bilirubin 0.7 mg/dL, all normal |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Completed today | 85 letters on the right and 84 on the left; color vision normal |
| Laboratory | Nucleic acid amplification test with rifampin resistance | At diagnosis | Up to date | Mycobacterium tuberculosis detected, rifampin resistance not detected, on the first sample |
| Laboratory | Sputum AFB smear and culture | Monthly until two consecutive cultures are negative | Completed today | Baseline smears 2+, 2+, and 3+; cultures growing Mycobacterium tuberculosis complex; release smears ordered for next week |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Ordered | Pending on the baseline isolate |
| Laboratory | HIV test | At diagnosis | Up to date | HIV-1/2 antigen and antibody test negative at diagnosis |
| Laboratory | Hepatitis B and C serology | At diagnosis | Up to date | Hepatitis B surface antigen, surface antibody, and core antibody negative; hepatitis C antibody negative; not immune to hepatitis B |
| Laboratory | Diabetes screen | At diagnosis | Up to date | HbA1c 5.2 percent at diagnosis |
| Imaging | Chest X-ray | At diagnosis; at two months only if the first cultures were negative; at the end of treatment as a new baseline | Up to date | Right upper lobe cavity at diagnosis |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | Thirteen of thirteen doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine 50 mg daily |
| Medication safety | Rifampin drug-interaction review | With every new medicine | Completed today | No other medicines; told that rifampin interacts with many drugs and stains contact lenses |
| Self-management | Home isolation and the criteria for release | Until three negative smears, clinical improvement, and two weeks of treatment | Completed today | Isolating at home with no visitors; off work |
| Referral | Contact investigation (household, coworkers, patients) | Led by the health department, from diagnosis | Referred | Health department testing his roommate and assessing coworkers and the patients he treated in the last three months; their results are not part of his record |
| Referral | Report to the local health department | At diagnosis | Up to date | Reported the day of diagnosis |
| Survey | Alcohol use (AUDIT-C for the past month) | Every visit | Completed today | AUDIT-C 4 for the past two weeks, down from 9 |
| Self-management | Brief counseling about alcohol and liver risk | Every visit | Completed today | Agreed goal of no alcohol during treatment |
| Referral | Counseling with a substance-use counselor | Every one to two weeks during treatment | Ordered | First video session next week |
| Medication safety | Medication for alcohol use disorder | Offered for alcohol use disorder | Not indicated | Acamprosate offered; he prefers counseling first for a mild disorder |
| Survey | Suicide-risk review and safety plan, with the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide; the 988 Suicide & Crisis Lifeline is in his phone |
| Referral | Infectious diseases consultation | Once at diagnosis, then as advised | Completed today | Seen today |

## Goal progress

- Complete 182 doses of treatment under video-observed therapy within six months. In progress; target 1873-08-18. **S**
- Sputum culture negative at two months. In progress; target 1873-08-18. **S**
- No alcohol during treatment, to protect his liver. In progress; target 1873-08-18. **S**
- Return to work once he is no longer infectious. In progress; target 1873-03-17. **S**
- Weight back to at least 64 kg by the end of treatment. In progress; target 1873-08-18. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases)
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Release smears next week. Five-week review with susceptibility results. Call the same day for hepatitis symptoms. **S**
- Next scheduled visit 1873-03-17: five-week review: susceptibility results, release from isolation, and liver monitoring. **S**
